1061: Bicalutamide 150 mg for Early non-Metastatic Prostate Cancer in Patients Who Would Otherwise Undergo Watchful Waiting: Latest Results at a Median 5.4 Years' Follow-up | Zendy

AI Assistant Blog Pricing

1061: Bicalutamide 150 mg for Early non-Metastatic Prostate Cancer in Patients Who Would Otherwise Undergo Watchful Waiting: Latest Results at a Median 5.4 Years' Follow-up

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.